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BMS Cypher Xience SES Test1 SES Test2 p (DES vs. BMS)
Angiography
%stenosis 36  12 23  14 29  10 20  8 23  8 0.014
Histology
%stenosis 60  23 47  8 30  10 40  14 41  11 0.019
Neointimal
area mm2
3.9  0.6 3.3  0.9 1.9  0.8 2.5  0.6 2.4  0.6 0.006
Injury score 1.3  0.6 0.8  0.5 0.9  0.5 0.9  0.5 0.9  0.4 0.18
Inﬂammation
score
1.6  0.6 1.2  0.5 0.8  0.4 1.0  0.3 0.9  0.5 0.06
%
endothelialization
99  1 95  4 94  3 93  3 96  1 0.016
Fibrin score 0.1  0.2 1.7  0.5 1.4  0.4 1.3  0.6 1.2  0.5 0.003







SConclusions: The tested SES showed an antiproliferative efﬁcacy similar to control
SES and EES, and signiﬁcantly less restenosis than BMS. All DES showed equivalent
levels of low endothelialization and higher ﬁbrin score than BMS, although the injury
and inﬂammation scores were similar in all groups.
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Background: The drug-eluting balloons (DEBs) have demonstrated a high anti-
proliferative efﬁcacy in the treatment and prevention of restenosis. Nevertheless, not
all the available devices are equally effective; so, the comparison of the results in
a preclinical model is relevant. Our objective is to assess the preclinical efﬁcacy and
safety of different DEBs.
Methods: In 17 domestic swine (253 kg), we implanted 51 Cobalt-Chromium
metallic stents (Architect, iVascular, Spain), one stent per major coronary artery.
Stent postdilatation was performed with different balloons to achieve high stent-
artery ratios (1.21  0.14). We used bare control balloons (n¼10), Test1 (DEB
Essential, iVascular; n¼15), Test2 (Modiﬁed Essential -more hydrophilic matrix,
iVascular; n¼16), and commercial DEBs (In.Pact Falcon, Medtronic, USA;
n¼10). Restenosis values (%diameter stenosis, late loss by angiography and %area
stenosis, neointimal area by histomorphometry) and vascular healing parameters
(injury score, endothelialization rate, ﬁbrin and inﬂammation scores) were analyzed
at 28 days.
Results: All the DEBs showed similar stenosis values at follow-up, signiﬁcantly lower
than bare controls: angiographic, 912 vs 3418% (p<0.0001); histomorphometric,
228 vs 5118% (p<0.0001). The injury (0.60.5) and inﬂammation scores
(0.80.3) were uniformly low in all the groups. As a marker of the pharmacologic
effect, we observed lower values of endothelialization rate (8710 vs 992%,
p¼0.0007) and higher ﬁbrin scores (2.10.7 vs 0.40.5, p<0.0001) in all the DEB
groups than in controls.Control Test1, Essential Test2, Mod. Essential In.Pact p (DEBs vs. control)
Angiography
%stenosis 33  18 10  15 8  8 12  12 0.0001
Late loss 1.3  0.5 0.4  0.5 0.3  0.3 0.5  0.4 0.0001
Histology
%stenosis 51  18 20  8 21  6 26  9 0.0001
Neointimal area mm2 3.4  1.2 1.5  0.7 1.7  0.4 1.9  0.8 0.0001
Injury score 0.9  0.6 0.6  0.3 0.5  0.5 0.6  0.6 0.29
Inﬂammation score 0.9  0.2 0.8  0.3 0.8  0.2 0.9  0.4 0.47
% endothelialization 99  1 86  12 84  11 93  4 0.0007
Fibrin score 0.4  0.5 2.3  0.8 2.2  0.5 1.7  0.8 0.0001Conclusions: In this preclinical model, the analyzed DEBs showed a signiﬁcant
reduction in restenosis as compared with control balloons after stent implantation. No
data of increased injury score or persistent inﬂammation was observed, but the
delayed endothelialization and ﬁbrin accumulation suggest a response to the drug
deposition.
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Background: Conventional Seldinger access has been the standard of care for over 60
years. It is performed at a relatively steep 45 angle that results in relatively high axialB242 JACC Vol 62/18/Suppl B j October 27–November 1, 2013 jtension in the artery wall; this in turn theoretically impedes closure of the access site.
A novel technology, AXERA (Arstasis, Redwood City), creates a shallow angle
arteriotomy that signiﬁcantly increases the tissue overlap within the cannulated track.
By taking advantage of the patient's own arterial pressure and the much lower axial
tension, Axera provides a degree of self-sealing. This animal testing was designed to
address whether or not the longer, shallower access track increases risk of dissection
or pseudoaneurysm or potentially impedes healing.
Methods: AXERA and control (Seldinger access) arteriotomy were performed on
contralateral femoral artery vessels in seven sheep. The vessels were examined
histologically 30 days postoperatively after step sectioning through the entire arte-
riotomy site. Histologic sections collected at each level of approximately 200 microns
were stained by H&E and modiﬁed Movat pentachrome.
Results: Creation of the arteriotomy site was successful for both methods in all 14
arteries. There was no evidence of vascular aneurysms or ectasia, medial dissection,
or luminal thrombosis. Vascular healing in both groups was mainly characterized by
transmural deposition of proteoglycan with inﬁltrating smooth muscle cells
accompanied by varying degrees of neoangiogenesis. Inﬂammation was generally
minimal to mild with rare giant cells. Mild to moderate calciﬁcation, mostly
involving the media, was noted in 6 arteries from 4 of 7 animals (3 Axera, 3
control) and is likely inherent to this pre-clinical model of injury. Advanced healing
in both groups was indicated by the absence of ﬁbrin and near complete endothelial
coverage.
Conclusions: The data indicate that healing after AXERA access is similar to standard
Seldinger access technique with no evidence of dissection or pseudoaneurysm. This
study histologically reafﬁrms the safety proﬁle of the Axera device evidenced by the
clinical results of the SECURE II and RECITAL trials.
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Background: Watchman (WM, Boston Scientiﬁc, Natick, MA) and Amplatzer
Cardiac Plug (ACP, St. Jude Medical, St. Paul, MN) are the most commonly used
LAA closure devices in patients with non-valvular atrial ﬁbrillation. WM has a para-
chute-shape designed to sit within the ostium of the LAA. The ACP has a disc and
lobe design, utilizing the disc to cover the LAA os. The impact of both devices on
local anatomy as well as healing response following placement ex vivo and in vivo in
a canine model at 28 days was evaluated.
Methods: WM (21mm) and ACP (16mm) devices were implanted in an adult canine
heart ex vivo to evaluate device surface area and conformation to the LAA. Both
devices (n¼3/group) with 10% larger than the LAA os in size were deployed in six
adult dogs under TEE and ﬂuoroscopy guidance and histology analyzed at 28 days.
Results: WM conformed to the LAA os without intrusion of left upper pulmonary
vein (LUPV) and mitral valve (MV), and was seated tightly in the LAA os. Space
from either inferior or superior edges to the MV (inf-to-MV, measured 9.31.2 mm)
and LUPV (sup-to-LUPV) allowed room for ablation. In comparison, the disc of the
ACP clearly extended to both the LUPV and MV. In vivo, the inf-to-MV from the disc
of ACP extended beyond the mitral leaﬂet, and its sup-to-LUPV impinged into the
lateral ridge beneath the LUPV, potentially limiting access for other procedures (eg.
pulmonary vein isolation). On histology, both devices were covered by mature
connective tissue with intermittent areas of early-organized ﬁbrin and thrombus. The
surface of WM inclusive of the threaded insert was completely endothelialized, but the
inferior edge and end-screw hub of the ACP disc were uncovered. WM had a greater
granulation tissue response and less ﬁbrin deposition than ACP, while ACP had
a greater inﬂammatory response.
Conclusions: These data demonstrate that conformation to the LAA and surrounding
structures is different between WM and ACP LAA closure devices, and may have an
effect on and the healing response following placement. Due to the design of the WM
device, it does not obstruct or impact adjacent structures.
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Background: The use of cryo-balloon ablation for pulmonary vein (PV) isolation has
led to questions as to how best to optimize single procedure success. Speciﬁcally,
what new indicators can be identiﬁed to better determine ideal ablation durations as
well as the best catheter orientations and catheter placements in the PV antra. Here we
present unique data obtained by observing PV antral cryo-balloon ablation under
direct vision.TCT Abstracts/POSTER/Basic Science, Animal Models, and Cell Therapy
